[Bio CEO Interview] RudaCure CEO Yongho Kim pursues active investigación conjunta with Hanlim Pharmaceutical, including RCI001 Phase 1 ensayo clínicos, to overcome the limitations of bio-ventures
http://www.medigatenews.com/news/2535905009
"Securing diverse pipelines beyond enfermedad de ojo seco to establish ourselves as a company that overcomes bio-venture limitations"
RudaCure's I+D pipeline — including RCI001 as well as tratamiento del dolor RCI002, atopic dermatitis tratamiento RCI003, metastatic cancer tratamiento RCI004, and AMD/age-related macular degeneration tratamiento RCI005 — consists entirely of tratamientos for trastornos sensoriales related to quality of life.
RCI002 is planned to undergo preensayo clínicos este año, with DS/DP producción in the following year, and Phase 1 ensayo clínicos in 2023. Actualmente, in vitro eficacia studies are underway.